Literature DB >> 10475315

The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain.

J L Lichtor1, F B Sevarino, G P Joshi, M A Busch, E Nordbrock, B Ginsberg.   

Abstract

UNLABELLED: Pharmacokinetic studies have shown that oral transmucosal absorption of fentanyl is relatively rapid compared with gastrointestinal absorption, and it results in increased bioavailability. We designed this study to establish the relative potency of oral transmucosal fentanyl citrate (OTFC) compared with i.v. morphine in 133 postoperative patients. The morning after surgery, patients randomly received one dose of either OTFC (200 or 800 microg) and a placebo i.v. injection or i.v. morphine (2 or 10 mg) and an oral transmucosal placebo unit. Pain intensity, pain relief, time to meaningful pain relief, and time to remedication were recorded. Median time to onset of relief was approximately 5 min for all groups. Over the first hour, little difference among treatment groups was seen for pain intensity and pain relief. By 2 h after study drug administration, 800 microg of OTFC and 10 mg of i.v. morphine generally produced similar analgesia, which was better than the smaller doses. Duration of analgesia with the larger doses (800 microg of OTFC and 10 mg of morphine) was similar and longer that produced by the smaller doses. The larger doses of OTFC and morphine produced better and more sustained analgesia than 200 microg of OTFC or 2 mg of morphine. IMPLICATIONS: The relative potency of oral transmucosal fentanyl citrate (OTFC) to i.v. morphine was 8-14:1. In this postoperative setting, OTFC produced rapid pain relief similar to that produced by i.v. morphine. The larger doses of OTFC (800 microg) and morphine (10 mg) produced better and more sustained analgesia than 200 microg of OTFC or 2 mg of morphine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10475315     DOI: 10.1097/00000539-199909000-00038

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  21 in total

Review 1.  Recent advances in clinical use of opioids.

Authors:  Eric Chevlen
Journal:  Curr Pain Headache Rep       Date:  2004-06

2.  Opioids and methadone equivalents for clinicians.

Authors:  W Victor R Vieweg; William F Carlyle Lipps; Antony Fernandez
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 3.  [Cancer breakthrough pain. Indications for rapidly effective opioids].

Authors:  J Kessler; H J Bardenheuer
Journal:  Anaesthesist       Date:  2011-07       Impact factor: 1.041

4.  The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.

Authors:  Diana Vivian Atigari; Kelly Frances Paton; Rajendra Uprety; András Váradi; Amy Frances Alder; Brittany Scouller; John H Miller; Susruta Majumdar; Bronwyn Maree Kivell
Journal:  Neuropharmacology       Date:  2020-12-28       Impact factor: 5.250

5.  Oral transmucosal fentanyl pretreatment for outpatient general anesthesia.

Authors:  P A Moore; M A Cuddy; J A Magera; A C Caputo; A H Chen; L A Wilkinson
Journal:  Anesth Prog       Date:  2000

6.  [Long-term pediatric opioid based pain control. Case reports].

Authors:  B Zernikow; C Schiessl; C Wamsler; N Griessinger; R Sittl
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

7.  Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats.

Authors:  John D Hoekman; Rodney J Y Ho
Journal:  Anesth Analg       Date:  2011-06-27       Impact factor: 5.108

Review 8.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Outpatient management of sickle cell pain with chronic opioid pharmacotherapy.

Authors:  Lauren Shaiova; David Wallenstein
Journal:  J Natl Med Assoc       Date:  2004-07       Impact factor: 1.798

10.  [Oral transmucosal fentanyl citrate for the treatment of breakthrough pain. Results of a non-interventional study (NIS)].

Authors:  R Zarth; M Ehmer; H-B Sittig
Journal:  Schmerz       Date:  2007-11       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.